Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

We aim to understand the fundamental biological processes underlying normal and malignant haematopoiesis and translate this to improve patient outcomes through new rational therapies.

Our group focuses on understanding the biological process of normal haematopoietic stem and progenitor cell differentiation and how this is disrupted during the development of blood malignancies. The ultimate goal of our work is to translate research findings into improved clinical outcomes through better use of existing treatments and the discovery of new and personalised therapies.  

Trajectory of Myeloid Malignancy 

Can we predict who will develop leukaemia later in life? Why do some abnormal cells develop into aggressive malignancies and others don’t? How does the microenvironment influence the emergence of cancerous cells in older age? We are interested in the molecular mechanisms that lead to malignant transformation of preleukemic progenitor cells and the evolution of established leukaemia resulting in therapy resistance or relapse.  

For this reason, our lab studies clonal architecture and heterogeneity of myeloid malignancies and preleukemic conditions such as transient abnormal myelopoiesis (TAM) in children with Down syndrome or clonal haematopoiesis of indeterminate potential (CHIP) in older people. We are also interested in the contribution of the bone marrow microenvironment to disease initiation and progression in such conditions. 

The application of multi-omics strategies (targeted and whole genome sequencing, single cell genomics and transcriptomics, flow cytometry and imaging) allows us to unravel evolutionary patterns within clonal trajectories and to identify cell-autonomous and non-cell-autonomous cues that influence the behaviour of individual clones. Using a wide array of techniques including gene editing and in vivo models we then can investigate the involvement of cell-intrinsic drivers such as epigenetic or transcriptional regulators as well as cell-extrinsic cues exerted by the microenvironment in the evolution of myeloid malignancies.  

T cell Responses to Myeloid Cancer 

Immune therapies offer the next frontier of targeted cancer treatments. Our lab has three interests in this area.  

First, we are studying the immunological basis of alloreactivity in allogeneic stem cell transplantation, the most established cancer cellular immunotherapy used to treat the highest risk blood cancers. We are using state-of-the-art integrated unbiased genomic and functional immunological assays to identify novel alloreactive antigens and the adaptive immune responses to these antigens to improve the outcomes for cancer patients.  

Second, we are studying the autologous immune response in patients treated for acute myeloid leukaemia (AML) to understand what role it plays in disease control.  

Third, we are investigating the changes in diversity and function of the T cell compartment through ageing. 

All three projects are linked and involve collaborative working with a number of immunology groups around Oxford and abroad. 

Drug Resistance and Response 

A central question in modern medicine is why most drugs fail to cure cancer patients. We are addressing this question in the context of AML. Patients diagnosed with this aggressive blood cancer have a poor clinical outcome mainly due to high relapse rates following treatment. Relapse is driven by therapy-resistant cells that are able to escape the therapy, remodel and dominate the blood ecosystem. In our lab we aim to understand the cellular and molecular basis of resistance by using state-of-the-art single cell methods (single-cell transcriptome, genotyping, ATAC-seq and multiparameter flow cytometry) to study patient AML samples. This highly translational work may provide novel tailored treatment options for patients. 


The group’s research work is supported by the well-established Haematopoietic Cell Biobank, one of the largest haematological sample biobanks in the UK (around 14,000 samples), which is coordinated and managed by our lab.  

We perform high quality processing of blood, bone marrow and biopsy samples from patients with haematological malignancies and healthy volunteers, and securely store the samples on-site alongside relevant anonymised clinical data. All of our Biobank procedures are performed in compliance with Good Clinical Practice (GCP) and Human Tissue Act (HTA) regulations.  

The Biobank is a powerful resource providing national and international collaborators access to samples for ethically approved research projects. Through this collection of invaluable patient specimens, the Biobank ultimately aims to facilitate better understanding of the biology of blood cancers and to improve patient outcomes through improved use of existing therapy and discovery of new therapies.

Our team


1. Persephone Borrow (University of Oxford)

2. Ronjon Chakraverty (University of Oxford)

3. Irene Roberts (University of Oxford)

4. Courtney DiNardo (MD Anderson Cancer Center)

5. Marina Konopleva (MD Anderson Cancer Center)

6. Charles Craddock (University of Birmingham)

7. Claus Nerlov (University of Oxford)

8. Thomas Höfer (DKFZ)

9. Peter Valk (Erasmus Cancer Institute)

10. Jurjen Versluis (Erasmus University Rotterdam)

11. John Dick (UHN Research)

12. Stephanie Xie (UHN Research)

13. Stefan Constantinescu ( Université catholique de Louvain’s de Duve Institute & Ludwig Cancer Research)

14. Owen Sansom (University of Glasgow)

15. Bristol Myers Squibb 

Clinical Studies and trials

Chief Investigator: Prof Paresh Vyas

JNJ 617 ALE 001 & JNJ 617 ALE 002 - Phase I/Ib Menin inhibitor trials in acute leukaemia. 

BMS CA059-001 - Phase I anti-SIRPα inhibitor in combination with other therapies in AML. 

IMGN632-0802 - Anti-CD123 antibody-drug conjugate with other therapies in AML.

ALIDHE  - Phase III study of ivosidenib with azacytidine in newly diagnosed IDH1 mutant AML patients ineligible for intensive chemotherapy.

HOVON 173Phase III study of ivosidenib with azacytidine with or without venetoclax in newly diagnosed IDH1 mutant AML patients ineligible for intensive chemotherapy.

Camellia – First-in-class Phase I trial of Humanized Monoclonal Antibody anti-CD47 in Acute Myeloid Leukemia. This is an academically funded, 7-year collaboration between my laboratory and Weissman Laboratory Stanford University. Sponsored by Stanford University. Oxford University is Sponsor in the EU. Oxford Oncology Clinical Trials Unit is running this multi-centre UK trial. Please note that Bloodwise is now Blood Cancer UK.

Lab Alumni

Alice Norton

Alison Kennedy

Alex Sternberg

Alice Norton

Anne de Groot

Anna Corby

Anna Schuh

Batchimeg Usukhbayar

Boris Guyot

Bilyana Stoilova

Catherine Garnett

Connor Sweeney

Christianne Kuhl

Dimitris Karamitros

Gaetan Juban

Gerda Mickute

Georg Otto

Grigore Gafencu

Helen Doolittle

Isla Hamlett

Jessica Doondeea

Joanna Bonnici

Julia Draper

Kelly Perkins

Kelly Soady

Ludovic Lhermitte

Lynn Quek

Marina Samitch

Marlen Metzner

Mirian Angulo Salazar

Natalia Garcia Martin

Natalie Sakakini

Neil Rodrigues

Nicolas Goardon

Pengjun Xi

Rachel Moore

Sarah Gooding

Sinead Hayes

Terri Cornforth

Vasiliki Symeonidou

Veronica Valverde-Garduno

Zahra Aboukhalil 

Members of the lab have been involved in public engagement activities at the MRC Festival of  Medical Research and the Royal Society Summer Science Exhibition

We regularly host both work experience students and visiting biomedical/medical science students. 

Professor Vyas has given short talks about AML and the importance of single-cell approaches to study a heterogeneous disease.

Related research themes